Glycotope GmbH
DCprime and Glycotope announce licensing agreement and collaboration (news with additional features)
Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime BV, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement and research collaboration. Under the agreement, DCprime has obtained the global research and commercialization rights to certain process development patents owned by Glycotope. In addition, the companies have initiated a research collaboration to evaluate novel immunotherapeutic approaches to solid tumours, based on the combination of their proprietary technologies. Henner Kollenberg, Managing Director, Glycotope commented: “This is an exciting opportunity and we look forward to working with DCprime. Through this collaboration we will look to draw on DCprime’s expertise in the development of dendritic cell therapies and combine this with our own knowledge of glyco-biology to evaluate potential new immunotherapies.” About Glycotope GmbH
DCprime: End of Media Release Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=WGMSBCIIMT Document title: 20180716_DCprime-Glycotope_PR_FINAL_contacts Issuer: Glycotope GmbH Key word(s): Research/Technology
18.07.2018 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. |